|
|
Profile
|
Delegates :
Masaki Sudo |
|
Incorporated :
February 19 , 2008 |
Paid in Capital :
3241 Million yen |
Employees :
93 人 |
Address :
8F Meieki Southside Square 1-21-19 Meieki Minami Nakamura-ku, Nagoya AICHI
〒450-0003
|
TEL/FAX :
+81-52-446-6100 / |
URL：
https://www.raqualia.com/en/ |
Attachment :
|
Mission/Background :
RaQualia Pharma, Inc. is a Nagoya-based drug discovery venture founded in 2008 following the spin-out of researchers from Pfizer's former central research laboratories in Japan. The company focuses on small-molecule drug discovery in gastrointestinal, pain, metabolic, and animal health fields, with a core business model of out-licensing innovative drug candidates.
Its research activities are conducted at Nagoya University and Shonan iPark. Drugs originating from RaQualia's research include four marketed products, such as tegoprazan (K-CAB(R)) and the animal health products GALLIPRANT(R) and ENTYCE(TM)/ELURA(TM), with tegoprazan marketed in 19 countries as of February 2026. The company is strengthening long-term growth through expansion of its P-CAB franchise, in-house R&D, and targeted protein degradation technologies. |
|
Technology & Business
|
-Discovery and development of pharmaceutical compounds
-Sales and licensing of intellectual property related to drug seeds and clinical candidate compounds
-Collaborative drug discovery partnerships with pharmaceutical companies and academic institutions
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Tegoprazan (R)
|
Launched
|
Treatment for gastroesophageal reflux disease (GERD)
|
|
Grapiprant (R)
|
Launched
|
Osteoarthritis (dogs)
|
|
Capromorelin (R)
|
Launched
|
Anorexia (dogs) Management of weight loss with CKD (cats)
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
In 2025, the Company achieved record-high revenue and returned to profitability, driven by increased royalty income from its flagship gastric acid therapy, tegoprazan. Medium- to long-term earnings were strengthened by a successful U.S. Phase III trial and a favorable result in Korean patent litigation, as well as progress through an expanded alliance with HK inno.N, a Japan licensing agreement, and higher research collaboration revenue at FIMECS.
|
|
Alliance strategy
|
The Company focuses on its proprietary small-molecule drug discovery platform and actively promotes open innovation with academia, biotech ventures, and pharmaceutical companies. Through early-stage collaborative research, it aims to increase the value of drug discovery programs and pursue out-licensing and strategic partnerships, balancing early monetization with mid- to long-term royalty income.
|
|
|